Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) drug. It stops HIV from entering the body and making copies of itself. The medicine is given as an injection every six months and is the longest-acting injectable so far.
Gilead plans regulatory processes by the end of 2024 in 18 low- and middle-income countries, including Botswana, Kenya, Uganda, South Africa, Nigeria, Tanzania, Zambia and Malawi. Late-stage trials showed a 96% reduction in infections among diverse groups. In the PURPOSE 2 study only two people out of more than 2,000 contracted HIV, and PURPOSE 1 found no cisgender women contracted HIV while on the drug.
Experts say price and reliable supply will shape real use. Early models suggest a year’s supply would need to cost about US$40 to reach wide uptake.
Difficult words
- pre-exposure prophylaxis — medicine given before infection to prevent disease
- long-acting — stays effective for many months
- regulatory — related to government approval rules
- trial — a test of a new medicinetrials
- reduction — a decrease in amount or number
- uptake — people's acceptance or use of something
- supply — the amount of medicine available to people
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Would you prefer a medicine given every six months? Why or why not?
- How could a low price help more people use the drug?
- What problems can a poor supply of medicine cause?
Related articles
PAHO issues first guide for tungiasis treatment
PAHO has published the first evidence-based guide to treat tungiasis, recommending low-viscosity dimethicone and warning against unsafe manual removal. The disease affects millions in Latin America, the Caribbean and Sub-Saharan Africa.
Worry about police linked to heart risk in Black women
A US study of 422 Black women found that worry about police interactions—especially concern for their children—was associated with thicker carotid artery measurements, a marker of cardiovascular risk. The study shows correlation, not causation.
Warm temperatures in pregnancy linked to loss of male fetuses in Sub-Saharan Africa
A study of nearly three million births across 33 Sub‑Saharan African countries found first‑trimester exposure above 20°C linked to higher loss of male fetuses. Authors cite the "frail male" idea and call for stronger maternal care.